Coeptis Therapeutics Launches Coeptis Technologies with Completion of NexGenAI Affiliates Network Platform Acquisition
DENVER, Colo., Dec 26, 2024 (247marketnews.com)- Coeptis Therapeutics (NASDAQ: COEP) completed its acquisition of the NexGenAI Affiliates Network platform and launched Coeptis Technologies, a new division that is strategically aimed at diversifying the Company’s growth potential.
Dave Mehalick, President and CEO of Coeptis Therapeutics, commented, “We are excited to integrate the NexGenAI Affiliates Network platform and its AI and RPA-driven tools into our offerings. In industries like biotech, pharma, and MLM, where competition is so high and regulatory challenges are complex, having advanced tools to optimize marketing, streamline operations, and drive measurable results is critical.
“In highly competitive industries such as biotech, pharma, and MLM, having advanced tools to optimize marketing, streamline operations, and drive measurable results is not just beneficial—it’s essential for our success.”
The Lead Advisory behind the development of the NexGenAI Affiliates Network platform, Anshuman Dash, stated, “The integration of NexGenAI’s innovative AI-powered marketing solutions with Coeptis Therapeutics’ forward-thinking approach marks a transformative step forward. This acquisition aligns nicely with Coeptis’ mission to drive innovation in highly regulated industries, revolutionize marketing strategies and operational efficiencies and ultimately deliver greater value to the partners and the industries served.”
About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.
24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.
CONTACT:
24/7 Market News
Editor@247marketnews.com
Related news for (COEP)
- Coeptis Therapeutics to Pursue Phase 2 Program Using Proprietary First-in-Class Allogeneic NK Cell Therapy for the Treatment of Viral Infections
- Coeptis Therapeutics President and CEO Issues Letter to Shareholders Highlighting 2023 Accomplishments and Outlook for 2024
- Coeptis Therapeutics to Present at the Emerging Growth Conference